The research at a glance

Human studies of GHK-Cu

1994: GHK-Cu gel for diabetic foot ulcers

Mulder and colleagues enrolled 181 patients in a randomized, evaluator-blinded study of a topical GHK-Cu gel. One comparison involved ulcers on the sole of the foot: 28 patients received the gel immediately after debridement, the removal of damaged tissue, and 32 received its inactive base. Both groups also received wound care and pressure-relieving footwear.

Median wound-area reduction was 98.5% with GHK-Cu versus 60.8% with the control. Treatment could continue for eight weeks, followed by six weeks of observation; the endpoint used each person’s last assessment. Mulder et al., original trial and Table 3.

The median summarizes the center of the group’s results. A 98.5% median area reduction does not mean that 98.5% of patients healed completely. The result concerns that gel plus ulcer care; it does not supply a healing rate for an injected blend.

2006: GHK-Cu skin care after laser resurfacing

Miller and colleagues randomized patients to skin-care regimens with or without GHK-Cu after carbon dioxide laser resurfacing around the mouth. Thirteen people completed the study. Researchers used blinded assessments and computer analysis for redness, and assessed wrinkles, skin quality and patient satisfaction at 12 weeks.

The GHK-Cu group reported greater satisfaction with the change in skin quality. However, the between-group comparisons did not show a significant advantage for redness resolution, wrinkles or objective skin quality. Miller et al., original trial.

This study separates two outcomes that can sound alike in a summary: being happier with the result and having a larger measured improvement. It also measured GHK-Cu as an addition to a laser procedure, rather than as the only intervention.

2016: GHK-Cu serum and measured facial wrinkles

Badenhorst and colleagues enrolled 40 women; 39 completed eight weeks. Twenty participants compared a GHK-Cu formulation on the right side of the face with its control on the left. A three-dimensional instrument measured a selected wrinkle near the eye.

Mean wrinkle-volume reduction from baseline was 24.1% versus 15.0%; mean depth reduction was 20.3% versus 15.3%. Badenhorst et al., original paper and Tables 2–3.

That leaves a 9.1-percentage-point gap between the mean volume reductions. The active side was always the right side, and the control omitted both the peptide and its lipid carrier. Neither detail allows the result to be attributed cleanly to GHK-Cu alone.

Human reports involving BPC-157

The knee, bladder and intravenous reports share a lead author. They examine different conditions and routes, rather than independently repeating the same treatment study.

2021: BPC-157, with or without thymosin beta-4, for knee pain

Lee and Padgett reviewed records from 17 patients who received injections into the knee joint; 16 were reached by telephone. Twelve had received BPC-157 alone, and four had received BPC-157 with thymosin beta-4. Most had received treatment six to 12 months before the survey.

Eleven of the 12 BPC-157 recipients and three of the four combination recipients reported improvement in knee pain. The report had no untreated comparison group and used no standardized measure of function, stiffness or daily activities. Lee and Padgett, original report.

This is a partial-combination report: GHK-Cu was absent. The two small groups also cannot establish that adding thymosin beta-4 improves or reduces the effect of BPC-157. Pain reports alone do not document repaired cartilage or a healed tear.

2024: BPC-157 and interstitial cystitis symptoms

Lee, Walker and Ayadi reported on 12 women with interstitial cystitis, a chronic bladder-pain condition. They had not responded to pentosan polysulfate, an oral medicine used for that condition. BPC-157 was injected locally around inflamed bladder tissue during a camera examination called cystoscopy. All underwent a repeat examination at six weeks; most completed the symptom questionnaire four to six months after treatment.

Ten women reported complete symptom resolution, and two rated the treatment’s success at 80%. No adverse events were reported. These were uncontrolled observations from a retrospective review, and the later questionnaire timing varied. Lee et al., original bladder study.

The report gives an early account of a specific local treatment. Its symptom ratings do not establish how it compares with another treatment, whether the result lasts longer, or whether GLOW affects bladder symptoms.

2025: Intravenous BPC-157 in two adults

Lee and Burgess monitored two adults who had previously received intravenous BPC-157. The pilot recorded vital signs and selected blood tests before and after infusions, with observations extending across three days.

The authors reported no side effects during the observation period and interpreted the laboratory changes as clinically insignificant. Lee and Burgess, original pilot study.

Two previously exposed people provide very limited information about first-use reactions, uncommon adverse events or longer-term effects. This was a short safety observation, with no injury-healing or skin outcome. The GLOW peptide side-effects guide examines how such findings relate to the wider safety questions.

September 2026: BPC-157 use documented in clinical notes

A preprint posted on September 7, 2026 analyzed clinical notes for 1,039 documented BPC-157 users. It had not undergone peer review when this guide was checked. Researchers used machine-assisted extraction with physician validation.

Scroll to compare all columns →

The paper’s 79% improvement figure uses the 354 people with an assessable response as its denominator. It does not describe 79% of all 1,039 users. Other therapeutic agents were recorded alongside BPC-157 for 525 people. The notes also contained adverse-event reports affecting the nervous system or mental health, skin or injection sites, and the digestive system. Venkatakrishnan et al., original preprint.

Missing outcomes for roughly two-thirds of users and concurrent treatments prevent a reliable success-rate calculation. Routine clinical notes also cannot establish adverse-event incidence. The study describes documented experience, without isolating BPC-157’s effect or providing a GLOW-specific result.

Human trials of specific thymosin beta-4 preparations

Full-length thymosin beta-4 and a short fragment need separate evidence. One analytical study identified the TB-500 preparation it tested as N-acetylated LKKTETQ, a seven-amino-acid sequence. The clinical preparations below are longer molecules. A shared name does not establish identical composition. Ho et al., original TB-500 analysis. The GLOW peptide stack guide explains the ingredient distinctions.

2015: Full-length thymosin beta-4 eye drops for dry eye

Sosne and Ousler randomized 72 adults with moderate to severe dry eye to a full-length, 43-amino-acid thymosin beta-4 eye-drop preparation or its vehicle, with 36 people assigned to each group. Treatment lasted 28 days, and 69 participants completed the trial.

The two primary comparisons were made on day 29:

Scroll to compare all columns →

Staining records dye uptake on the eye’s surface; discomfort is a symptom rating. Both used 0–4 scales, with lower scores indicating better results. Neither between-group difference reached statistical significance. Some secondary analyses favored the peptide, including a smaller increase in discomfort during a controlled dry-eye challenge. Sosne and Ousler, original trial.

Primary endpoints are the main tests specified for judging a trial. The secondary results offer reasons for further investigation, while the trial’s main tests did not establish benefit. All these findings concern that eye-drop preparation.

2021: Recombinant thymosin beta-4 given intravenously

Wang and colleagues tested a specific 44-amino-acid recombinant thymosin beta-4 preparation, produced through genetic engineering, in healthy adults. The single-administration part enrolled 54 people, including placebo recipients; the repeated-administration part enrolled 30. Assessments continued through day 28 and included blood exposure, laboratory tests and adverse events.

Mild or moderate adverse events occurred in both active-treatment and placebo groups. The authors reported no serious adverse events or dose-limiting toxicities. Wang et al., original phase I trial.

This was an early safety and blood-exposure trial in healthy adults. It did not test injury recovery or skin improvement, and tolerability of that preparation cannot establish the safety of a three-ingredient blend.

Animal studies that help explain the research

2003: Thymosin beta-4 and a shorter fragment in wound repair

Philp and colleagues examined full-length thymosin beta-4 in animal wound models, including diabetic and aged mice. In 26-month-old mice, the authors also tested the seven-amino-acid fragment LKKTETQ and reported wound repair comparable to that seen with the parent molecule. The original abstract does not provide group sizes or a numerical effect size for that comparison. Philp et al., original wound study.

This gives the fragment its own experimental evidence. The tested LKKTETQ sequence should still be distinguished from N-acetylated LKKTETQ, and neither experiment establishes a human GLOW healing rate.

2022: BPC-157 blood exposure in rats and dogs

He and colleagues measured BPC-157 after intravenous and intramuscular administration in rats and beagle dogs. Their pharmacokinetic experiments used six rats per sampling point and six dogs across the dog study’s treatment periods.

Mean absolute bioavailability after intramuscular administration was approximately 14–19% in rats and 45–51% in dogs. Those figures compare blood exposure with the intravenous reference after accounting for the amount administered. Measured intact BPC-157 declined rapidly in plasma, with reported mean elimination half-lives below 30 minutes under the tested conditions. He et al., original pharmacokinetic study.

Half-life describes how quickly the measured plasma level falls; it does not by itself establish how long a biological effect lasts. These animal measurements cannot determine a human GLOW injection schedule. The GLOW peptide dosage guide explains why a measured quantity and an established treatment protocol require different evidence.

What would a direct GLOW study need to show?

A useful human GLOW trial would identify all three ingredients and their molecular forms, specify the formulation and route, and compare the blend with a suitable control. It would define the intended outcome before collecting results and report adverse events alongside benefit measurements.

To test whether the ingredients work better together, the study would also need comparisons with the relevant individual ingredients or partial combinations. A benefit in one ingredient trial plus a benefit in another does not measure an added benefit from mixing them.

For a question such as skin texture, hair growth or injury recovery, the GLOW peptide benefits guide organizes the evidence by the result people are looking for.

Evidence checked September 14, 2026. This is a selected guide to original studies, including abstracts where full text was unavailable, and one clearly identified preprint. It is not a systematic review.